Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) announced an inducement equity grant under Nasdaq Listing Rule 5635(c)(4). The company granted 16,355 restricted stock units to nine newly hired non-executive officers, approved by the compensation committee and issued under the Ultragenyx Employment Inducement Plan.

The grants have a grant date of January 16, 2026 and vest over four years with 25% of the underlying shares vesting on each anniversary of the grant date, subject to continued employment as of each vesting date.

News Market Reaction – RARE

+0.41%

+0.41% Session close to close

In the Jan 26 session, RARE gained 0.41%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a grant of 16,355 restricted stock units to nine newly hired non-executive...

Analysis

This announcement details a grant of 16,355 restricted stock units to nine newly hired non-executive officers under an inducement plan, vesting 25% annually over four years. It reflects routine equity compensation rather than a strategic shift. In light of recent major events—such as preliminary $672M–$674M 2025 revenue and the mixed setrusumab Phase 3 outcome—investors may focus more on upcoming regulatory milestones and pivotal trial readouts than on this HR-related item.

Key Figures

Inducement RSUs: 16,355 units Employees granted: 9 employees Grant date: January 16, 2026 +2 more

5 metrics

Inducement RSUs 16,355 units Granted to nine newly hired non-executive officers

Employees granted 9 employees Recipients of inducement restricted stock units

Grant date January 16, 2026 RSU grant date under Ultragenyx Employment Inducement Plan

Vesting period 4 years RSUs vest over four years subject to continued employment

Annual vesting rate 25% per year 25% of shares vest on each grant-date anniversary

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 12	Preliminary 2025 results	Positive	+8.3%	Preliminary 2025 revenue growth and multiple 2026 regulatory and clinical catalysts outlined.
Jan 07	Conference presentation	Neutral	-4.1%	Announcement of J.P. Morgan Healthcare Conference presentation and webcast access details.
Dec 30	DTX401 BLA completion	Positive	+1.0%	Completion of DTX401 BLA supported by data from 52 treated patients over six years.
Dec 29	Setrusumab Phase 3 data	Negative	-42.3%	Orbit and Cosmic trials missed primary fracture endpoint despite BMD gains and stable safety.
Dec 19	Prior inducement grant	Neutral	+3.7%	Grant of 13,144 RSUs to new non-executive officers under inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows strong alignment between news tone and price moves: positive financial/clinical milestones have seen gains, while the failed Phase 3 fracture endpoint triggered a sharp selloff.

Recent Company History

Over the past months, Ultragenyx has reported key clinical and financial updates. On Dec 29, 2025, negative Phase 3 results for setrusumab led to a -42.32% move, while completing the DTX401 BLA on Dec 30, 2025 saw a modest gain. Preliminary 2025 revenue of $672M–$674M and catalysts highlighted on Jan 12, 2026 correlated with an 8.26% rise. A prior inducement grant on Dec 19, 2025 coincided with a smaller uptick, framing today’s HR-related grant as part of routine equity compensation activity.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"reported the grant of 16,355 restricted stock units of the company’s common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the new employees... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NOVATO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 16,355 restricted stock units of the company’s common stock to nine newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of January 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

What did Ultragenyx (RARE) announce on January 23, 2026 regarding stock awards?

Ultragenyx announced a grant of 16,355 restricted stock units to nine newly hired non-executive officers as an inducement under Nasdaq Rule 5635(c)(4).

When is the grant date and what is the vesting schedule for Ultragenyx RARE RSUs?

The grant date is January 16, 2026, and the RSUs vest over four years with 25% vesting each anniversary, subject to continued employment.

Why did Ultragenyx use Nasdaq Listing Rule 5635(c)(4) for the RARE inducement grant?

The company used Nasdaq Listing Rule 5635(c)(4) to classify the awards as an employment inducement for newly hired employees entering into employment with Ultragenyx.

How many employees received inducement RSUs in the Ultragenyx (RARE) grant?

Nine newly hired non-executive officers received the inducement restricted stock unit awards.

Who approved the Ultragenyx RARE inducement awards and under what plan?

The awards were approved by the company’s compensation committee and granted under the Ultragenyx Employment Inducement Plan.